• 2020 GAPNA Pharmacology Conference: Contemporary Pharmacology and Prescribing in Older AdultsJoin us at the 2020 GAPNA Pharmacology Conference:
    Contemporary Pharmacology and Prescribing in Older Adults

    April 14-18, 2020, Honolulu, HI.

    Earn up to 18 CNE hours.


    Find out more about it and REGISTER today!

  • 2019 Senior Report Senior Report: Older Americans have more options for home care, but still struggling.

    The United Health Foundation has released results of a sweeping new study benchmarking the health of older adults. The America's Health Rankings® Senior Report was created in partnership with GAPNA to improve the health of America's seniors.

    The data will help advanced practice nurses and other providers deliver quality care.

    Find out about it!

  • AwardNew for GAPNA members: MCM Education

    GAPNA has partnered with a MCM Education to offer an ongoing series of CNE programs available to GAPNA members. "Diagnosing and Managing Parkinson’s Disease in Older Adults," is the latest program offered.

    Parkinson’s disease (PD) is characterized by both motor and nonmotor symptoms. It is diagnosed based on the presence of two of four motor symptoms including rest tremor, bradykinesia, rigidity, and gait imbalance...

    Find out about it!

  • FREE continuing education credit is available for the following session:

    "Meaningful Conversations throughout the Course of Illness"

    (session captured at the GAPNA 2018 Annual Conference)

    For November/December 2019 - Get Your Free CNE Now!

Little Difference in Effectiveness of Drugs to Prevent Episodic Migraine in Adults

Migraine headaches affect 17 percent of women and 6 percent of men in the United States and fall into two classes: episodic migraines, defined as lasting less than 15 days per month, and chronic migraines that last at least 15 days per month for at least 3 months.

Even episodic migraines can cause serious lifestyle limitations, requiring preventive medication. All four drugs approved by the U.S. Food and Drug Administration for prevention of adult episodic migraine (the anti-epileptics, divalproex and topiramate, and the beta-blockers, timolol and propranolol) were found effective in a review of studies on the medications.

These drugs were better than placebo in reducing monthly migraine frequency by at least 50% in 200-400 patients per 1,000 treated, according to a the review of 215 randomized controlled trials and 76 nonrandomized studies. However, none of the approved drugs was significantly more beneficial than the others.

More details are in Shamiliyan et al. (2013). Preventive pharmacologic treatments for episodic migraine in adults. Journal of General Internal Medicine, 28(9), 1225-1237.

Related Topic 1: 

GAPNA Newsletter Issue: